MedTrace Logo

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

NCT05465954 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2026-01-12

No results posted yet for this study

Summary

This phase II trial tests the safety and side effects of efineptakin alfa and pembrolizumab in treating patients with glioblastoma that has come back (recurrent). Efineptakin alfa is an immunotherapy drug that works by helping the immune system fight tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving efineptakin alfa and pembrolizumab may kill more tumor cells in patients with recurrent glioblastoma.

Conditions

  • High Grade Astrocytic Tumor
  • Recurrent Glioblastoma, IDH-Wildtype
  • Recurrent Gliosarcoma

Interventions

PROCEDURE

Biospecimen Collection

Correlative studies

BIOLOGICAL

Efineptakin alfa

Given IM

BIOLOGICAL

Pembrolizumab

Given IV

PROCEDURE

Biopsy

Undergo tumor biopsy

Sponsors & Collaborators

Principal Investigators

  • Jian L. Campian, MD, PhD · Mayo Clinic in Rochester

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-24
Primary Completion
2027-10-15
Completion
2028-10-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05465954 on ClinicalTrials.gov